SEC Comment Letter for BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149) (BIVI) — Jun 9, 2016
BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149)
Date: June 9, 2016 · CIK: 0001580149 · Accession: 0000000000-16-079933
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4720 June 9 , 2016 Jonathan Adams Chief Executive Officer Nanoantibiotics, Inc. 100 Cummings Center, Suite 247 -C Beverly, Massachusetts 01915 Preliminary Information Statement on Schedule 14C Filed April 21, 2016 File No. 000 -55292
Re: NanoAntibiotics, Inc. Current Report on Form 8K Filed April 15, 2016 File No. 000 -55292
Dear Mr. Adams :
We have completed our review of your filings . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing s and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act o f 1934 and all applicable rules require.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4720 June 9 , 2016 Jonathan Adams Chief Executive Officer Nanoantibiotics, Inc. 100 Cummings Center, Suite 247 -C Beverly, Massachusetts 01915 Re: NanoAntibiotics, Inc. Current Report on Form 8K Filed April 15, 2016 File No. 000 -55292 Preliminary Information Statement on Schedule 14C Filed April 21, 2016 File No. 000 -55292 Dear Mr. Adams : We have completed our review of your filings . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing s and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act o f 1934 and all applicable rules require. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance